Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|April 8, 2023
Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancerLuca Boscolo Bielo, Dario Trapani, Giuseppe CuriglianoCurrent Opinion in Oncology|August 25, 2023
HER2-positive breast cancer: cotargeting to overcome treatment resistancePaola Zagami, Luca Boscolo Bielo, Eleonora Nicolò, et al.Therapeutic Advances in Medical Oncology|February 27, 2023
The HER2-low revolution in breast oncology: steps forward and emerging challengesEleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, et al.Cancer Treatment and Research|January 4, 2024
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast CancerBeatrice Taurelli Salimbeni, Emanuela Ferraro, Luca Boscolo Bielo, et al.Expert Opinion on Drug Metabolism & Toxicology|September 11, 2023
A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugsLuca Boscolo Bielo, Stefano Natangelo, Jalissa Katrini, et al.Cancer Journal (Sudbury, Mass.)|November 16, 2022
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?Eleonora Nicolò, Matteo Repetto, Luca Boscolo Bielo, et al.Cancers|September 9, 2022
Targeting Cellular Components of the Tumor Microenvironment in Solid MalignanciesCarmen Belli, Gabriele Antonarelli, Matteo Repetto, et al.Investigational New Drugs|May 25, 2022
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046Matteo Repetto, Edoardo Crimini, Liliana Ascione, et al.Breast (Edinburgh, Scotland)|March 30, 2023
Future potential targets of antibody-drug conjugates in breast cancerChiara Corti, Luca Boscolo Bielo, Ambra Carnevale Schianca, et al.Current Opinion in Oncology|August 22, 2022
Postneoadjuvant treatment for triple-negative breast cancerDario Trapani, Emanuela Ferraro, Federica Giugliano, et al.Pageof 4